UNITED STATES OF AMERICA
before the
SECURITIES AND EXCHANGE COMMISSION
SECURITIES EXCHANGE ACT OF 1934
Release No. 76919 / January 15, 2016
Admin. Proc. File No. 3-16906

In the Matter of
ACCENTIA BIOPHARMACEUTICALS, INC.,
and
BIOSTEM U.S. CORP.

NOTICE THAT INITIAL DECISION HAS BECOME FINAL
The time for filing a petition for review of the initial decision in this proceeding has
expired. No such petition has been filed by Accentia Biopharmaceuticals, Inc., or Biostem U.S.
Corp., and the Commission has not chosen to review the decision on its own initiative.
Accordingly, notice is hereby given, pursuant to Rule 360(d) of the Commission's Rules
of Practice,1 that the initial decision of the administrative law judge has become the final
decision of the Commission with respect to Accentia Biopharmaceuticals, Inc., and Biostem U.S.
Corp.2 The order contained in that decision is hereby declared effective. The initial decision
ordered that, pursuant to Section 12(j) of the Securities Exchange Act of 1934, the registrations
of each class of registered securities of Accentia Biopharmaceuticals, Inc., and Biostem U.S.
Corp., are revoked.
For the Commission, by the Office of the General Counsel, pursuant to delegated
authority.

Brent J. Fields
Secretary

1
2

17 C.F.R. ยง 201.360(d).

Accentia Biopharmaceuticals, Inc., and Biostem U.S. Corp., Initial Decision Release No. 918
(Nov. 23, 2015), 112 SEC Docket 18, 2015 WL 7423037. The stock symbols and Central Index
Key numbers are: ABPI and 1310094 for Accentia Biopharmaceuticals, Inc.; and HAIR and
1455380 for Biostem U.S. Corp.

